An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.
09-26-2018 | Insulin | View from the clinic | Collection
Editorial Board member Jay Shubrook succinctly delivers his strategies for initiating insulin therapy for the first time in patients with type 2 diabetes.
Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.
The protective effect of empagliflozin against cardiovascular and all-cause mortality translates into between 1.0 and 4.5 years of additional life expectancy for high-risk patients with type 2 diabetes, say the EMPA REG OUTCOME investigators.
The cardioprotective effects of liraglutide apply to patients with chronic kidney disease as well as those with established cardiovascular disease, show two post-hoc analyses of the LEADER trial.
An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.
Researchers have identified a haplotype of three missense mutations in the sodium-glucose cotransporter-1 gene that is associated with a reduced risk for impaired glucose tolerance, diabetes, and obesity.
